RedHill Sells Talicia to Apotex for $18M Upfront, $35M in Milestones
Event summary
- RedHill Biopharma divested its 70% stake in Talicia to Apotex for $18M upfront plus up to $35M in milestone payments.
- The deal strengthens RedHill's liquidity and funds its commercial expansion strategy.
- Apotex previously acquired Cumberland Pharmaceuticals' 30% stake in Talicia.
- RedHill aims to reposition its commercial business toward larger product opportunities and operational profitability.
The big picture
RedHill's divestiture of Talicia aligns with its strategy to focus on larger product opportunities and accelerate revenue growth. The deal with Apotex provides immediate capital and potential upside, enabling RedHill to scale its gastrointestinal commercial franchise. This move reflects a broader trend in the biopharmaceutical industry where companies divest non-core assets to fund strategic growth initiatives.
What we're watching
- Strategic Execution
- How RedHill will deploy the $18M upfront payment to fund its commercial expansion and achieve operational profitability.
- Milestone Realization
- Whether RedHill can secure the additional $35M in milestone payments from Apotex based on Talicia's worldwide net sales.
- Product Pipeline
- The pace at which RedHill advances its key clinical late-stage development programs, including opaganib and RHB-102.
Related topics